|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACAT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ACSF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:80,001,389...80,043,796
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACSS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADGRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ADORA2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,648,867...137,697,580
Ensembl chr 6:131,831,454...131,854,463
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AKAP12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:52,208,035...52,240,293
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:82,038,679...82,055,478
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDOC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Anxa11 |
annexin A11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,410,756...1,457,797
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANXA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AOX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1b1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1B1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:84,093,529...84,144,835
Ensembl chr14:79,879,533...79,930,778
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1S2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:34,204,601...34,230,819
Ensembl chr X:30,572,751...30,597,262
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP2S1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:86,545,601...86,557,007
Ensembl chr 1:77,417,477...77,428,905
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AP3D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:28,547,205...28,554,383
Ensembl chr18:28,270,545...28,280,094
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:30,058,739...30,085,415
Ensembl chr18:29,807,536...29,833,555
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:170,126,573...170,148,624
Ensembl chr 5:164,844,161...164,866,212
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Arl4a |
ARF like GTPase 4A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL4A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:57,079,496...57,084,156
Ensembl chr 6:57,078,812...57,085,066
|
|
G |
Arl5a |
ARF like GTPase 5A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:57,287,599...57,312,488
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Atp5mg |
ATP synthase membrane subunit G |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5MG mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:54,122,457...54,130,407
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5PF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:37,368,045...37,375,721
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP6V0B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:131,423,387...131,426,401
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:16,984,084...17,007,156
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:177,676,205...177,699,575
Ensembl chr 2:175,378,517...175,401,883
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP9A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of B4GALT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:176,437,073...176,453,001
Ensembl chr 3:156,018,053...156,070,074
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCAR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCKDK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bex2 |
brain expressed X-linked 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BEX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:103,811,458...103,812,986
Ensembl chr X:99,019,000...99,021,503
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BIK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BNIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
C5h8orf88 |
similar to human chromosome 8 open reading frame 88 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of C8ORF88 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:28,330,167...28,355,691
Ensembl chr 5:28,330,206...28,357,152
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CACYBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:74,970,917...74,981,298
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CARD10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:112,210,944...112,252,044
Ensembl chr 7:110,330,408...110,359,224
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CASP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:119,513,007...119,564,802
Ensembl chr 8:110,635,710...110,686,417
|
|
G |
Ccdc92 |
coiled-coil domain containing 92 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC92 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:37,457,676...37,484,080
Ensembl chr12:31,796,684...31,823,337
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC93 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:32,607,618...32,675,993
Ensembl chr13:32,607,587...32,676,023
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CCND2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:48,655,549...48,661,786
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CD63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cd99l2 |
CD99 molecule-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD99L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:6,861,242...6,906,838
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CDC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of CDH1 mRNA; [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:51,303,414...51,353,900
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDKN1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:31,420,062...31,431,703
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:103,715,344...103,760,931
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cep192 |
centrosomal protein 192 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CEP192 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:63,643,816...63,728,264
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CFAP251 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,923,154...38,997,881
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHD9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:32,114,379...32,337,488
Ensembl chr19:15,942,687...16,164,556
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:44,517,862...44,534,144
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Chtop |
chromatin target of PRMT1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHTOP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:178,278,848...178,291,142
Ensembl chr 2:175,981,271...175,992,748
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CITED4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:139,532,165...139,533,056
Ensembl chr 5:134,246,682...134,248,135
|
|
G |
Cklf |
chemokine-like factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKLF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:704,528...712,998
Ensembl chr19:698,033...706,570
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:13,722,360...13,727,519
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CLCN6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:163,715,593...163,748,301
Ensembl chr 5:158,434,299...158,465,059
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CLDN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cnn2 |
calponin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cnpy4 |
canopy FGF signaling regulator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNPY4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:17,064,642...17,070,755
Ensembl chr12:17,064,642...17,070,043
|
|
G |
Coa3 |
cytochrome C oxidase assembly factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC56 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:86,220,192...86,221,173
Ensembl chr10:86,220,194...86,221,178
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COMMD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:101,081,667...101,185,738
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Coq3 |
coenzyme Q3 methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:35,429,567...35,460,613
Ensembl chr 5:35,429,574...35,460,607
|
|
G |
Coq5 |
coenzyme Q5, methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:46,977,632...46,994,575
Ensembl chr12:41,316,748...41,333,848
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of COTL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:64,780,309...64,814,629
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox16 |
cytochrome c oxidase assembly factor COX16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:101,162,231...101,181,277
Ensembl chr 6:101,019,680...101,181,246
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX7C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:18,577,145...18,579,170
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpa4 |
carboxypeptidase A4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:60,155,675...60,179,644
Ensembl chr 4:59,188,284...59,212,255
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:62,121,681...62,185,638
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Creb3l2 |
cAMP responsive element binding protein 3-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CREB3L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:66,874,623...66,990,962
Ensembl chr 4:65,907,655...66,023,763
|
|
G |
Cript |
CXXC repeat containing interactor of PDZ3 domain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CRIPT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:13,334,978...13,342,934
Ensembl chr 6:7,580,703...7,589,399
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:64,961,764...65,020,099
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSNK1E mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:112,863,726...112,887,338
Ensembl chr 7:110,983,318...111,006,794
|
|
G |
Cul1 |
cullin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CUL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:77,551,781...77,634,210
Ensembl chr 4:76,551,983...76,627,980
|
|
G |
Cuta |
cutA divalent cation tolerance homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CUTA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:5,022,956...5,024,580
Ensembl chr20:5,022,956...5,024,552
|
|
G |
Cwc15 |
CWC15 spliceosome-associated protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CWC15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:19,586,900...19,597,817
Ensembl chr 8:11,305,424...11,316,325 Ensembl chr 2:11,305,424...11,316,325
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CXXC5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,427,230...27,458,673
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYBA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYGB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:102,376,506...102,386,272
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp4x1 |
cytochrome P450, family 4, subfamily x, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CYP4X1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:133,888,439...133,923,254
Ensembl chr 5:128,651,776...128,682,779
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYSRT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:28,452,359...28,456,006
Ensembl chr 3:8,053,482...8,059,721
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DAPK3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:8,524,183...8,532,558
|
|
G |
Dbi |
diazepam binding inhibitor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:207,166,660...207,195,528
Ensembl chr 2:204,481,737...204,510,609
|
|
G |
Dcaf15 |
DDB1 and CUL4 associated factor 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DCAF15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCBLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:55,594,691...55,649,113
Ensembl chr11:42,125,787...42,179,697
|
|
G |
Dcp2 |
decapping mRNA 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:37,001,615...37,037,949
Ensembl chr18:36,750,732...36,788,557
|
|
G |
Dctn5 |
dynactin subunit 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCTN5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:186,120,415...186,137,146
Ensembl chr 1:176,689,156...176,705,906
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DDR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DECR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,609,389...15,617,779
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dennd1a |
DENN domain containing 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DENND1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:41,974,502...42,461,816
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DKK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnaaf10 |
dynein axonemal assembly factor 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAAF10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:91,618,649...91,639,828
Ensembl chr14:91,636,157...91,639,831
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:6,010,081...6,232,052
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnase1l1 |
deoxyribonuclease 1-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNASE1L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:157,208,230...157,216,812
Ensembl chr X:152,056,942...152,065,518
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:16,971,372...16,977,782
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EEF1D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:109,462,645...109,478,021
Ensembl chr 7:107,581,930...107,608,799
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EFNB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:68,297,529...68,310,335
Ensembl chr X:64,257,351...64,270,157
|
|
G |
Efnb2 |
ephrin B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EFNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:87,485,215...87,529,224
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EGR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELOVL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Elp6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELP6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ERH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:100,280,933...100,291,200
Ensembl chr 6:100,280,930...100,291,210
|
|
G |
Exoc2 |
exocyst complex component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:33,714,949...33,906,901
Ensembl chr17:33,506,338...33,693,289
|
|
G |
Exosc2 |
exosome component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOSC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:35,360,652...35,370,948
Ensembl chr 3:14,962,917...14,973,575
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EZR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F2RL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fam217b |
family with sequence similarity 217, member B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM217B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:165,505,574...165,515,273
Ensembl chr 3:165,501,532...165,513,377
|
|
G |
Fam98a |
family with sequence similarity 98, member A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FAM98A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:25,626,108...25,640,767
Ensembl chr 6:19,874,071...19,888,742
|
|
G |
Fance |
FA complementation group E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:6,371,153...6,388,366
Ensembl chr20:6,375,573...6,386,631
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:104,449,403...104,515,297
Ensembl chr14:100,248,875...100,314,255
|
|
G |
Fbxo2 |
F-box protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXO2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXW5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:28,720,670...28,725,237
Ensembl chr 3:8,322,543...8,327,092
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FEZ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGFR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:81,211,800...81,227,215
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgl1 |
fibrinogen-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:57,824,127...57,854,413
Ensembl chr16:51,120,694...51,151,093
|
|
G |
Fnbp1 |
formin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FNBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:34,706,814...34,826,770
Ensembl chr 3:14,309,640...14,424,881
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxj2 |
forkhead box J2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:157,718,990...157,745,468
Ensembl chr 4:156,046,969...156,073,518
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXO3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FST mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Ftsj1 |
FtsJ RNA 2'-O-methyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FTSJ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:16,915,087...16,929,426
Ensembl chr X:14,244,050...14,252,030
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GADD45A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt11 |
polypeptide N-acetylgalactosaminyltransferase 11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GALNT11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:10,571,464...10,604,974
Ensembl chr 4:9,837,629...9,871,140
|
|
G |
Gbp1 |
guanylate binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:231,398,163...231,432,131 Ensembl chr 2:231,398,163...231,432,131
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GJB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:35,375,977...35,393,817
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gldc |
glycine decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GLDC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:237,296,753...237,375,620
Ensembl chr 1:227,883,249...227,962,097
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIPR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:62,966,163...62,998,016
Ensembl chr 5:58,170,425...58,202,272
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIS3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:225,976,326...226,395,899
|
|
G |
Glmp |
glycosylated lysosomal membrane protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLMP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:176,092,098...176,095,688
Ensembl chr 2:173,794,255...173,799,960
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLRX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gng10 |
G protein subunit gamma 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GNG10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:78,651,167...78,658,060
Ensembl chr 5:73,856,164...73,863,012 Ensembl chr 5:73,856,164...73,863,012
|
|
G |
Gpc1 |
glypican 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GPC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:100,843,645...100,871,458
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPD1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Gpr137 |
G protein-coupled receptor 137 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPR137 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:213,558,846...213,562,422
Ensembl chr 1:204,129,636...204,133,082
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GRPEL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:78,517,049...78,522,868
Ensembl chr14:74,292,023...74,298,200
|
|
G |
Gtf2b |
general transcription factor IIB |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:234,427,734...234,446,043
Ensembl chr 2:231,767,238...231,785,651
|
|
G |
Gtf2f1 |
general transcription factor IIF subunit 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2F1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:1,931,033...1,940,197
Ensembl chr 9:1,843,901...1,853,423
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:65,997,472...66,019,530
Ensembl chr17:61,308,014...61,418,009
|
|
G |
Gypc |
glycophorin C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GYPC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,160,739...24,193,204
|
|
G |
Hirip3 |
HIRA interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HIRIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:190,903,065...190,905,610
Ensembl chr 1:181,472,056...181,475,079
|
|
G |
Hmgb3 |
high mobility group box 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:154,341,106...154,346,087
Ensembl chr X:149,296,375...149,301,292
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HNRNPA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:80,984,470...80,999,413
Ensembl chr 3:60,578,673...60,588,306
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HNRNPK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hoxb2 |
homeobox B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HOXB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:81,814,340...81,816,731
Ensembl chr10:81,318,026...81,320,192
|
|
G |
Hps6 |
HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HPS6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:254,802,250...254,804,859
Ensembl chr 1:244,853,194...244,855,883
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSD17B8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSPA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HSPB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:44,905,362...44,910,760
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Ino80c |
INO80 complex subunit C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INO80C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:15,653,508...15,752,455
Ensembl chr18:15,378,770...15,393,403
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ITGB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Itgb5 |
integrin subunit beta 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ITGB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:80,333,588...80,449,373
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Jag2 |
jagged canonical Notch ligand 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JAG2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,804,133...137,826,738
Ensembl chr 6:131,983,056...132,005,818
|
|
G |
Jmjd8 |
jumonji domain containing 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of JMJD8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,353,460...15,356,392
Ensembl chr10:14,848,980...14,851,879
|
|
G |
Jup |
junction plakoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JUP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,300,440...85,327,057
|
|
G |
Kat8 |
lysine acetyltransferase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KAT8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:191,954,827...191,967,107
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KLF6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:69,449,483...69,458,478
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Kntc1 |
kinetochore associated 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KNTC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,429,925...38,500,564
Ensembl chr12:32,769,020...32,839,561
|
|
G |
Krba1 |
KRAB-A domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRBA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:77,341,654...77,363,075
Ensembl chr 4:77,340,959...77,363,613
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:85,669,276...85,672,211
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:134,724,840...134,730,569
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Krt6c |
keratin 6c |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT6C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:134,678,316...134,682,753
Ensembl chr 7:132,799,616...132,804,045
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRTCAP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:176,952,167...176,956,163
Ensembl chr 2:174,654,219...174,658,405
|
|
G |
Lamtor4 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LAMTOR4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:22,372,269...22,376,090
Ensembl chr12:17,258,623...17,262,480
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LBH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:28,321,040...28,344,855
Ensembl chr 6:22,568,834...22,593,079
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LDLR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LIMA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:132,780,556...132,880,343
Ensembl chr 7:130,901,717...131,001,473
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LITAF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:5,163,258...5,199,930
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Lix1l |
limb and CNS expressed 1 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LIX1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:186,824,864...186,850,761
Ensembl chr 2:184,136,038...184,161,916
|
|
G |
Lmod3 |
leiomodin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LMOD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:131,400,643...131,415,411
Ensembl chr 4:129,843,970...129,858,244
|
|
G |
LOC100361879 |
ATP synthase subunit epsilon, mitochondrial-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5F1EP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:82,087,509...82,088,367
Ensembl chr14:77,863,571...77,863,729
|
|
G |
LOC120094551 |
U6 spliceosomal RNA |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNU6-1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:72,489,442...72,489,548
Ensembl chr 8:63,594,040...63,594,146 Ensembl chr14:63,594,040...63,594,146 Ensembl chr15:63,594,040...63,594,146 Ensembl chr17:63,594,040...63,594,146 Ensembl chr X:63,594,040...63,594,146 Ensembl chr17:63,594,040...63,594,146 Ensembl chr10:63,594,040...63,594,146 Ensembl chr14:63,594,040...63,594,146 Ensembl chr11:63,594,040...63,594,146 Ensembl chr15:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr 3:63,594,040...63,594,146 Ensembl chr X:63,594,040...63,594,146 Ensembl chr 5:63,594,040...63,594,146 Ensembl chr14:63,594,040...63,594,146 Ensembl chr 7:63,594,040...63,594,146 Ensembl chr13:63,594,040...63,594,146 Ensembl chr 8:63,594,040...63,594,146 Ensembl chr 9:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr16:63,594,040...63,594,146 Ensembl chr16:63,594,040...63,594,146 Ensembl chr 9:63,594,040...63,594,146 Ensembl chr15:63,594,040...63,594,146 Ensembl chr 5:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr 6:63,594,040...63,594,146 Ensembl chr 1:63,594,040...63,594,146 Ensembl chr14:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr 6:63,594,040...63,594,146 Ensembl chr 3:63,594,040...63,594,146 Ensembl chr18:63,594,040...63,594,146 Ensembl chr 5:63,594,040...63,594,146 Ensembl chr 6:63,594,040...63,594,146 Ensembl chr 1:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr18:63,594,040...63,594,146 Ensembl chr18:63,594,040...63,594,146 Ensembl chr 6:63,594,040...63,594,146 Ensembl chr 2:63,594,040...63,594,146 Ensembl chr X:63,594,040...63,594,146 Ensembl chr 6:63,594,040...63,594,146 Ensembl chr10:63,594,040...63,594,146 Ensembl chr 7:63,594,040...63,594,146 Ensembl chr 4:63,594,040...63,594,146
|
|
G |
LOC120099557 |
U6 spliceosomal RNA |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNU6-15P mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:46,990,999...46,991,105
Ensembl chr X:46,990,999...46,991,105
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LPIN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lrrc20 |
leucine rich repeat containing 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LRRC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:29,965,673...30,071,185
Ensembl chr20:29,422,925...29,528,369
|
|
G |
Luzp1 |
leucine zipper protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LUZP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:153,989,570...154,065,071
Ensembl chr 5:148,706,138...148,781,609
|
|
G |
Lyrm2 |
LYR motif containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LYRM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:47,198,192...47,200,470
Ensembl chr 5:47,198,185...47,201,611
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MANF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:116,427,053...116,430,259
Ensembl chr 8:107,548,352...107,551,438
|
|
G |
Map7d1 |
MAP7 domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MAP7D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:143,812,467...143,837,597
Ensembl chr 5:138,527,401...138,552,499
|
|
G |
Mat2b |
methionine adenosyltransferase 2 non-catalytic beta subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MAT2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:25,609,202...25,626,694
Ensembl chr10:25,106,930...25,122,777
|
|
G |
Mbtps1 |
membrane-bound transcription factor peptidase, site 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MBTPS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:64,470,245...64,521,438
Ensembl chr19:47,561,598...47,612,791
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MCM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:22,155,921...22,163,320
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Med7 |
mediator complex subunit 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MED7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:30,842,330...30,857,873
Ensembl chr10:30,842,292...30,859,220
|
|
G |
Mfsd3 |
major facilitator superfamily domain containing 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MFSD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:110,300,254...110,304,108
Ensembl chr 7:108,421,350...108,423,461
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:137,582,152...137,590,294
Ensembl chr 2:135,431,283...135,439,612
|
|
G |
Mgat2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGAT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:93,392,416...93,394,905
Ensembl chr 6:87,656,349...87,658,177
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MLKL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:56,186,860...56,213,886
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MMACHC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:135,403,094...135,409,285
Ensembl chr 5:130,166,451...130,172,601
|
|
G |
Mms19 |
MMS19 homolog, cytosolic iron-sulfur assembly component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MMS19 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:250,706,595...250,743,604
Ensembl chr 1:240,757,282...240,794,288
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MPDZ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:100,812,121...100,966,566
Ensembl chr 5:95,766,118...95,920,499
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:54,244,920...54,256,064
Ensembl chr 8:45,348,285...45,359,298
|
|
G |
Mrpl32 |
mitochondrial ribosomal protein L32 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:50,565,133...50,568,000
Ensembl chr17:50,565,055...50,568,010
|
|
G |
Mrpl35 |
mitochondrial ribosomal protein L35 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL35 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:105,424,076...105,431,844
Ensembl chr 4:103,865,812...103,880,887
|
|
G |
Mrps18c |
mitochondrial ribosomal protein S18C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS18C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:9,116,688...9,122,943
Ensembl chr14:8,791,330...8,818,516
|
|
G |
Mrps21 |
mitochondrial ribosomal protein S21 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS21 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:186,095,729...186,103,351
Ensembl chr 2:183,406,792...183,414,372
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MSH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:25,179,400...25,320,857
|
|
G |
Mt2 |
metallothionein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtfr2 |
mitochondrial fission regulator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTFR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:16,942,814...16,958,218
Ensembl chr 1:15,070,894...15,148,832
|
|
G |
Mtif3 |
mitochondrial translational initiation factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTIF3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:13,240,091...13,251,350
Ensembl chr12:8,126,276...8,140,470
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTURN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:85,137,825...85,158,790
Ensembl chr 4:83,807,579...83,824,950
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MVD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:67,404,911...67,414,974
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Myadm |
myeloid-associated differentiation marker |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYADM mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:74,779,616...74,796,752
Ensembl chr 1:65,864,173...65,874,035
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYH9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Myl6 |
myosin light chain 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:1,495,301...1,498,512
Ensembl chr 7:910,774...933,791
|
|
G |
Myl6b |
myosin light chain 6B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:40,572,012...40,572,991
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Myo1b |
myosin Ib |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYO1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:49,690,086...49,850,798
|
|
G |
Mzf1 |
myeloid zinc finger 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MZF1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:82,742,709...82,755,069
Ensembl chr 1:73,670,541...73,681,635
|
|
G |
Mzt2b |
mitotic spindle organizing protein 2B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MZT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:85,024,120...85,031,960
Ensembl chr11:85,024,315...85,031,167
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NASP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928
|
|
G |
Nav2 |
neuron navigator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:107,799,968...108,458,546
Ensembl chr 1:98,663,759...99,322,337
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NCAPD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:157,968,815...157,992,020
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NDRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndufa12 |
NADH:ubiquinone oxidoreductase subunit A12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFA12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:30,658,316...30,685,302
Ensembl chr 7:28,771,330...28,798,315
|
|
G |
Ndufb3 |
NADH:ubiquinone oxidoreductase subunit B3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:67,623,417...67,633,629
Ensembl chr 9:60,129,154...60,139,446
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:117,447,605...117,461,943
Ensembl chr 2:115,519,154...115,533,589
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:55,400,543...55,410,181
|
|
G |
Nelfe |
negative elongation factor complex member E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NELFE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,981,259...3,987,016
Ensembl chr20:3,976,518...3,982,355
|
|
G |
Neu1 |
neuraminidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NEU1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,897,480...3,901,745
|
|
G |
Nkiras2 |
NFKB inhibitor interacting Ras-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NKIRAS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:86,055,029...86,062,398
Ensembl chr10:85,557,944...85,562,072
|
|
G |
Nol6 |
nucleolar protein 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NOL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:61,055,863...61,083,249
Ensembl chr 5:56,260,830...56,270,336
|
|
G |
Npm3 |
nucleophosmin/nucleoplasmin, 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NPM3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:244,595,638...244,597,623
Ensembl chr 1:244,595,644...244,597,591
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NPTX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:105,309,578...105,318,829
Ensembl chr10:104,811,403...104,820,367
|
|
G |
Nsl1 |
NSL1 component of MIS12 kinetochore complex |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:105,176,163...105,205,179
Ensembl chr13:102,649,058...102,674,054
|
|
G |
Nudt2 |
nudix hydrolase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUDT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:61,424,176...61,439,018
Ensembl chr 5:56,628,265...56,643,104
|
|
G |
Nufip2 |
nuclear FMR1 interacting protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUFIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:63,072,964...63,105,823
Ensembl chr10:62,574,882...62,600,346
|
|
G |
Osbp |
oxysterol binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OSBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:218,313,455...218,343,263
Ensembl chr 1:208,887,895...208,918,506
|
|
G |
Ost4 |
oligosaccharyltransferase complex subunit 4, non-catalytic |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OST4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:31,191,198...31,192,422
|
|
G |
Pabpc1l |
poly(A) binding protein, cytoplasmic 1-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PABPC1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:173,111,856...173,145,389
Ensembl chr 3:152,693,700...152,725,997
|
|
G |
Pak1ip1 |
PAK1 interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PAK1IP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:23,742,217...23,753,325
Ensembl chr17:23,741,414...23,753,324
|
|
G |
Pbdc1 |
polysaccharide biosynthesis domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PBDC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:70,154,106...70,197,827
Ensembl chr X:70,154,106...70,184,552
|
|
G |
Pccb |
propionyl-CoA carboxylase subunit beta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PCCB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:110,470,197...110,520,222
Ensembl chr 8:101,590,737...101,641,234
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PDIA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PFKFB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,522,371...118,565,478
Ensembl chr 8:109,643,937...109,685,634
|
|
G |
Phactr3 |
phosphatase and actin regulator 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PHACTR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:185,582,134...185,801,404
Ensembl chr 3:165,205,255...165,423,153
|
|
G |
Phldb2 |
pleckstrin homology-like domain, family B, member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PHLDB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:68,321,738...68,540,724
Ensembl chr11:54,859,135...55,078,467
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLAT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plec |
plectin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLEC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:109,768,447...109,829,798
Ensembl chr 7:107,887,764...107,945,467
|
|
G |
Plk2 |
polo-like kinase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxnb2 |
plexin B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLXNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:122,111,917...122,138,201
Ensembl chr 7:120,232,331...120,258,330
|
|
G |
Poc1a |
POC1 centriolar protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:115,801,335...115,869,812
Ensembl chr 8:106,922,978...106,991,089
|
|
G |
Poglut3 |
protein O-glucosyltransferase 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of POGLUT3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,673,811...62,691,606
Ensembl chr 8:53,777,785...53,795,399
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLE2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:93,410,713...93,448,782
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Polr3k |
RNA polymerase III subunit K |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLR3K mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:168,982,812...168,987,040
|
|
G |
Pop5 |
POP5 homolog, ribonuclease P/MRP subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POP5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:47,037,451...47,045,778
Ensembl chr12:41,376,755...41,381,336
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppic |
peptidylprolyl isomerase C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:49,040,690...49,053,296
Ensembl chr18:46,842,409...46,855,017
|
|
G |
Ppil3 |
peptidylprolyl isomerase like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:67,460,594...67,474,325
Ensembl chr 9:59,964,919...59,979,886
|
|
G |
Ppp1r14c |
protein phosphatase 1, regulatory (inhibitor) subunit 14c |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PPP1R14C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:42,177,977...42,358,654
Ensembl chr 1:39,773,403...39,886,956
|
|
G |
Ppp6r2 |
protein phosphatase 6, regulatory subunit 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPP6R2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:122,164,968...122,236,625
Ensembl chr 7:120,285,406...120,356,395
|
|
G |
Ppwd1 |
peptidylprolyl isomerase domain and WD repeat containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPWD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:35,337,301...35,360,661
Ensembl chr 2:35,335,962...35,360,460
|
|
G |
Prickle1 |
prickle planar cell polarity protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PRICKLE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:126,518,587...126,614,581
Ensembl chr 7:124,639,142...124,658,113
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:50,740,808...50,743,292
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:55,737,852...55,740,218
Ensembl chr10:55,239,241...55,241,586
|
|
G |
Psmg4 |
proteasome assembly chaperone 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMG4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:30,710,682...30,718,035
Ensembl chr17:30,710,682...30,718,082
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:73,585,729...73,671,868
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTGES mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:34,575,643...34,586,987
|
|
G |
Ptpre |
protein tyrosine phosphatase, receptor type, E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTPRE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,774,195...199,924,646
Ensembl chr 1:190,344,401...190,489,534
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PTTG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PYCARD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Qrich1 |
glutamine-rich 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of QRICH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,095,435...118,135,001
Ensembl chr 8:109,217,376...109,261,359
|
|
G |
Rab25 |
RAB25, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:176,298,124...176,304,221
Ensembl chr 2:174,000,323...174,006,422
|
|
G |
Rab38 |
RAB38, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB38 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:142,182,556...142,262,924
|
|
G |
Rab8a |
RAB8A, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RAB8A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:17,688,049...17,709,412
Ensembl chr16:17,654,034...17,675,678
|
|
G |
Rad23b |
RAD23 homolog B, nucleotide excision repair protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAD23B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:74,885,518...74,923,621
Ensembl chr 5:70,090,232...70,128,319
|
|
G |
Ralgdsl1 |
ral guanine nucleotide dissociation stimulator like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:67,184,402...67,454,019
Ensembl chr13:64,635,246...64,904,191
|
|
G |
Rasip1 |
Ras interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RASIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:105,233,599...105,246,028
Ensembl chr 1:96,091,074...96,109,562
|
|
G |
Rbck1 |
RANBP2-type and C3HC4-type zinc finger containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RBCK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:161,249,389...161,266,321
Ensembl chr 3:140,789,080...140,806,005
|
|
G |
Rbm33 |
RNA binding motif protein 33 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:7,714,660...7,825,469
Ensembl chr 4:6,983,970...7,089,918
|
|
G |
Rbm5 |
RNA binding motif protein 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:117,298,866...117,328,107
Ensembl chr 8:108,420,222...108,449,430
|
|
G |
Rbms1 |
RNA binding motif, single stranded interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBMS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:45,195,828...45,420,406
Ensembl chr 3:45,197,972...45,420,376
|
|
G |
Rer1 |
retention in endoplasmic reticulum sorting receptor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RER1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:170,916,643...170,929,073
Ensembl chr 5:165,634,300...165,646,750
|
|
G |
Rfxank |
regulatory factor X-associated ankyrin-containing protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RFXANK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:19,314,307...19,322,827
Ensembl chr16:19,281,475...19,460,255
|
|
G |
Rgs17 |
regulator of G-protein signaling 17 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGS17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:44,627,583...44,729,957
Ensembl chr 1:42,227,070...42,324,609
|
|
G |
Rgs20 |
regulator of G-protein signaling 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RGS20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:14,484,436...14,614,317
Ensembl chr 5:14,534,775...14,614,084
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHEB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:11,012,173...11,053,860
Ensembl chr 4:10,279,370...10,320,160
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHOB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoq |
ras homolog family member Q |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RHOQ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:13,368,499...13,403,929
Ensembl chr 1:106,622,141...106,623,699
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM65B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,323,867...40,548,092
|
|
G |
Rnaset2 |
ribonuclease T2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNASET2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:55,133,532...55,150,701
Ensembl chr 1:52,585,929...52,603,147
|
|
G |
Rnf126 |
ring finger protein 126 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF126 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:10,590,013...10,597,585
Ensembl chr 7:9,938,229...9,946,738
|
|
G |
Rnf20 |
ring finger protein 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:68,771,507...68,797,240
Ensembl chr 5:63,976,045...64,001,754
|
|
G |
Rnh1 |
ribonuclease/angiogenin inhibitor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:205,698,882...205,711,348
Ensembl chr 1:196,269,293...196,281,910
|
|
G |
Rpl10a |
ribosomal protein L10A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL10A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:6,390,533...6,393,091
Ensembl chr20:6,385,823...6,391,357 Ensembl chr 9:6,385,823...6,391,357
|
|
G |
Rpl27 |
ribosomal protein L27 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL27 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:86,875,758...86,879,457
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl34 |
ribosomal protein L34 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL34 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:221,958,551...221,962,309
Ensembl chr 2:219,284,382...219,288,111 Ensembl chr17:219,284,382...219,288,111
|
|
G |
Rpp25l |
ribonuclease P/MRP subunit p25 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPP25L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:61,674,299...61,675,844
Ensembl chr 5:56,876,316...56,880,013
|
|
G |
Rpusd2 |
RNA pseudouridine synthase domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPUSD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:126,471,620...126,476,869
Ensembl chr 3:106,017,864...106,023,251
|
|
G |
Rragd |
Ras-related GTP binding D |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RRAGD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:52,170,234...52,205,700
Ensembl chr 5:47,373,463...47,409,356
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of S100A10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SC5D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scara3 |
scavenger receptor class A, member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SCARA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:44,315,422...44,348,416
Ensembl chr15:40,140,161...40,172,894
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SCD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sdhaf2 |
succinate dehydrogenase complex assembly factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHAF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:216,564,002...216,592,877
Ensembl chr 1:207,139,112...207,168,616
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:158,547,775...158,568,589
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Sec13 |
SEC13 homolog, nuclear pore and COPII coat complex component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:148,433,344...148,446,735
Ensembl chr 4:146,875,524...146,891,173
|
|
G |
Sec61g |
Sec61 translocon subunit gamma |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC61G mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:90,899,766...90,906,143
Ensembl chr14:90,899,768...90,906,162 Ensembl chr 9:90,899,768...90,906,162
|
|
G |
Selenon |
selenoprotein N |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SEPN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:152,032,330...152,046,707
Ensembl chr 5:146,748,652...146,763,059
|
|
G |
Selenos |
selenoprotein S |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SELS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:129,070,240...129,080,007
Ensembl chr 1:119,659,751...119,669,833
|
|
G |
Sem1 |
SEM1 26S proteasome subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:35,638,306...35,658,462
Ensembl chr 4:34,671,848...34,692,005
|
|
G |
Serpinb1a |
serpin family B member 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:24,051,933...24,065,032
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SFXN4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:269,962,527...269,984,849
Ensembl chr 1:259,976,481...259,998,754
|
|
G |
Sgpp2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SGPP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:87,211,155...87,331,787
Ensembl chr 9:79,763,284...79,880,457
|
|
G |
Sh2b3 |
SH2B adaptor protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SH2B3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:40,391,755...40,414,336
Ensembl chr12:34,731,911...34,753,616
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC26A6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,438,110...118,448,271
Ensembl chr 8:109,559,642...109,569,778
|
|
G |
Slc43a3 |
solute carrier family 43, member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC43A3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:90,414,822...90,450,654
Ensembl chr 3:70,009,313...70,029,749
|
|
G |
Slc44a1 |
solute carrier family 44 member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC44A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:72,857,323...73,037,279
Ensembl chr 5:68,063,618...68,241,909
|
|
G |
Slf2 |
SMC5-SMC6 complex localization factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:253,731,979...253,794,577
Ensembl chr 1:243,782,246...243,845,250
|
|
G |
Snip1 |
Smad nuclear interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:142,613,028...142,620,502
Ensembl chr 5:137,328,371...137,335,845
|
|
G |
Snord96a |
small nucleolar RNA, C/D box 96A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNORD96A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:33,672,228...33,672,307
Ensembl chr10:33,171,093...33,171,172
|
|
G |
Snrnp25 |
small nuclear ribonucleoprotein U11/U12 subunit 25 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNRNP25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,420,482...15,423,806
Ensembl chr10:15,420,486...15,423,804
|
|
G |
Snx8 |
sorting nexin 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,365,746...19,414,333
Ensembl chr12:14,251,859...14,300,432
|
|
G |
Sox15 |
SRY-box transcription factor 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SOX15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:54,871,793...54,873,497
Ensembl chr10:54,372,403...54,376,591
|
|
G |
Spa17 |
sperm autoantigenic protein 17 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPA17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:45,496,175...45,507,262
Ensembl chr 8:37,307,557...37,318,639
|
|
G |
Spats2l |
spermatogenesis associated, serine-rich 2-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPATS2L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:66,814,217...66,988,084
Ensembl chr 9:59,320,276...59,493,967
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPHK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Sphk2 |
sphingosine kinase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPHK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:105,317,332...105,324,985
Ensembl chr 1:96,180,887...96,188,391
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:89,106,809...89,111,926
Ensembl chr15:82,692,143...82,698,009
|
|
G |
Srp54a |
signal recognition particle 54A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SRP54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:78,322,308...78,362,017
Ensembl chr 6:72,587,605...72,625,189
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ST14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:29,540,811...29,581,517
|
|
G |
Stk26 |
serine/threonine kinase 26 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of STK26 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:130,325,064...130,375,674
Ensembl chr X:130,310,885...130,374,291
|
|
G |
Stmn1 |
stathmin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STMN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stx8 |
syntaxin 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:53,154,572...53,393,912
Ensembl chr10:52,654,990...52,894,993
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:96,707,951...96,709,650
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tamm41 |
TAM41 mitochondrial translocator assembly and maintenance homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TAMM41 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:149,743,216...149,776,388
Ensembl chr 4:148,018,463...148,103,694
|
|
G |
Tbc1d31 |
TBC1 domain family, member 31 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TBC1D31 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:89,427,354...89,506,894
Ensembl chr 7:89,426,780...89,506,894
|
|
G |
Tbc1d32 |
TBC1 domain family, member 32 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TBC1D32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:35,902,281...36,133,161
Ensembl chr20:35,359,863...35,590,415
|
|
G |
Tcea2 |
transcription elongation factor A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:189,173,756...189,181,633
Ensembl chr 3:168,796,331...168,804,116
|
|
G |
Tceal3 |
transcription elongation factor A like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:104,802,966...104,804,926
Ensembl chr X:100,010,690...100,012,654 Ensembl chr X:100,010,690...100,012,654
|
|
G |
Tceal9 |
transcription elongation factor A like 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:104,037,274...104,039,345
Ensembl chr X:99,228,458...99,247,763
|
|
G |
Tcerg1 |
transcription elongation regulator 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TCERG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:34,756,558...34,817,441
Ensembl chr18:34,505,751...34,566,470
|
|
G |
Tent5b |
terminal nucleotidyltransferase 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM46B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:150,979,238...150,986,548
Ensembl chr 5:145,695,362...145,706,073 Ensembl chr11:145,695,362...145,706,073
|
|
G |
Tfb1m |
transcription factor B1, mitochondrial |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFB1M mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:44,115,240...44,161,737
Ensembl chr 1:44,119,166...44,161,709
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFPI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of THBD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Timm22 |
translocase of inner mitochondrial membrane 22 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM22 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:61,751,686...61,759,444
Ensembl chr10:61,253,450...61,261,755
|
|
G |
Timm23 |
translocase of inner mitochondrial membrane 23 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM23 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:7,416,590...7,442,681
Ensembl chr16:7,409,688...7,436,379 Ensembl chr 3:7,409,688...7,436,379 Ensembl chr 6:7,409,688...7,436,379
|
|
G |
Tinf2 |
TERF1 interacting nuclear factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TINF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:33,140,611...33,146,930
Ensembl chr15:29,170,652...29,176,984
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tmem44 |
transmembrane protein 44 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM44 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:83,685,191...83,725,254
Ensembl chr11:70,181,345...70,216,958
|
|
G |
Tmem50b |
transmembrane protein 50B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM50B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:44,290,805...44,323,650
Ensembl chr11:30,804,837...30,837,661
|
|
G |
Tmem54 |
transmembrane protein 54 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TMEM54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:141,449,191...141,455,683
Ensembl chr 5:141,449,191...141,455,682
|
|
G |
Tmub2 |
transmembrane and ubiquitin-like domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMUB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:87,738,662...87,743,118
Ensembl chr10:87,238,548...87,242,779
|
|
G |
Tnc |
tenascin C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfaip8l3 |
TNF alpha induced protein 8 like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TNFAIP8L3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:63,309,683...63,351,687
Ensembl chr 8:54,414,457...54,500,079
|
|
G |
Tomm6 |
translocase of outer mitochondrial membrane 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:13,304,269...13,305,637
|
|
G |
Tomm7 |
translocase of outer mitochondrial membrane 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:12,197,503...12,204,344
Ensembl chr 4:11,305,110...11,311,962
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TP63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tpd52l1 |
TPD52 like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TPD52L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:26,172,170...26,291,109
|
|
G |
Tpd52l2 |
TPD52 like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of TPD52L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:188,972,321...188,995,721
Ensembl chr 3:168,594,609...168,619,762
|
|
G |
Trim33 |
tripartite motif-containing 33 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TRIM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:193,495,743...193,588,595
Ensembl chr 2:190,807,243...190,888,814
|
|
G |
Trim47 |
tripartite motif-containing 47 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TRIM47 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:101,836,465...101,840,936
Ensembl chr10:101,337,573...101,342,044
|
|
G |
Tsen15 |
tRNA splicing endonuclease subunit 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSEN15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:67,040,134...67,055,509
Ensembl chr13:64,490,218...64,505,617
|
|
G |
Tspan9 |
tetraspanin 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TSPAN9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:162,500,029...162,681,699
Ensembl chr 4:160,813,879...160,995,501
|
|
G |
Tspo |
translocator protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSPO mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:116,600,214...116,610,461
Ensembl chr 7:114,720,188...114,730,450
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TUBB2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,747,503...30,800,714
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TWIST1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXNIP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ube2j1 |
ubiquitin-conjugating enzyme E2, J1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2J1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:52,218,807...52,237,805
Ensembl chr 5:47,422,587...47,441,461
|
|
G |
Ube2n |
ubiquitin-conjugating enzyme E2N |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2N mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:32,041,190...32,071,252
Ensembl chr 7:30,154,616...30,184,355
|
|
G |
Uimc1 |
ubiquitin interaction motif containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UIMC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:9,528,923...9,597,967
Ensembl chr17:9,527,794...9,592,799
|
|
G |
Uros |
uroporphyrinogen III synthase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UROS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:197,920,827...197,943,183
Ensembl chr 1:188,490,323...188,512,249
|
|
G |
Usp13 |
ubiquitin specific peptidase 13 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of USP13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:117,502,811...117,617,049
Ensembl chr 2:115,577,091...115,686,222
|
|
G |
Vasn |
vasorin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VASN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:11,424,174...11,434,681
Ensembl chr10:10,917,605...10,928,357
|
|
G |
Vps37b |
VPS37B subunit of ESCRT-I |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS37B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,220,973...38,249,935
Ensembl chr12:32,560,047...32,589,014
|
|
G |
Vps72 |
vacuolar protein sorting 72 homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS72 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:185,367,329...185,379,199
Ensembl chr 2:182,678,609...182,690,182
|
|
G |
Wasf2 |
WASP family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of WASF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:150,620,733...150,685,943
Ensembl chr 5:145,336,842...145,399,242
|
|
G |
Xpnpep1 |
X-prolyl aminopeptidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of XPNPEP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:262,006,761...262,057,479
Ensembl chr 1:252,001,367...252,051,479
|
|
G |
Zc3h4 |
zinc finger CCCH-type containing 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZC3H4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:86,234,457...86,271,963
Ensembl chr 1:77,106,250...77,142,691
|
|
G |
Zfp185 |
zinc finger protein 185 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZNF185 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:155,874,138...155,919,921
Ensembl chr X:150,831,862...150,874,810
|
|
G |
Zswim1 |
zinc finger, SWIM-type containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZSWIM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:153,559,104...153,562,821
Ensembl chr 3:153,558,970...153,562,915
|
|
G |
Zyx |
zyxin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZYX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:72,203,991...72,213,181
Ensembl chr 4:71,237,451...71,246,553
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:116,248,571...116,272,917
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ABCA1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ABCG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ACAA2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:70,620,310...70,648,417
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ACSBG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:63,887,433...63,943,486
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ACSF2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:80,001,389...80,043,796
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ACSS1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:139,450,383...139,500,325
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts2 |
ADAM metallopeptidase with thrombospondin type 1 motif, 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ADAMTS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:35,422,030...35,627,483
Ensembl chr10:34,921,049...35,123,821
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ADGRL1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:41,107,162...41,148,752
Ensembl chr19:24,204,360...24,244,139
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of ADIPOQ mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ADIPOQ protein |
CTD |
PMID:37021957 PMID:38954831 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of ADRB3 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr16:71,544,603...71,547,410
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of AKAP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:74,118,232...74,151,366
Ensembl chr10:73,621,883...73,653,896
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of ALDH2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDOC protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:135,454,517...135,470,183
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of AMPD3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPT2 protein |
CTD |
PMID:38954831 |
|
NCBI chr16:77,790,760...77,841,241
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl3 |
angiopoietin-like 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPTL3 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd50 |
ankyrin repeat domain containing 50 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ANKRD50 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:121,466,275...121,500,758
Ensembl chr 2:121,468,573...121,500,752
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ANPEP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:143,176,645...143,219,447
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ANTXR1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:119,590,771...119,778,232
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of APC2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:10,043,010...10,065,037
Ensembl chr 7:9,392,336...9,414,310
|
|
G |
Aplp1 |
amyloid beta precursor like protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of APLP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:94,824,330...94,834,705
Ensembl chr 1:85,696,882...85,707,155
|
|
G |
Aplp2 |
amyloid beta precursor like protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of APLP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:37,857,407...37,920,487
Ensembl chr 8:29,599,230...29,661,855
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of APOE mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Aqp7 |
aquaporin 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of AQP7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:60,968,495...60,982,618
Ensembl chr 5:56,172,519...56,186,642
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ARHGAP18 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:18,403,537...18,637,256
|
|
G |
Arhgap6 |
Rho GTPase activating protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ARHGAP6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:28,525,912...29,062,344
Ensembl chr X:24,953,464...25,488,663
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ARHGEF2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ARRDC3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ARRDC4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:131,779,436...131,793,438
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Asip |
agouti signaling protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:163,933,768...164,021,377
Ensembl chr 3:143,555,696...143,561,171
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,070,754...73,388,902
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:83,772,988...84,759,439
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ATF3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp10d |
ATPase phospholipid transporting 10D (putative) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ATP10D mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:36,265,696...36,366,460
Ensembl chr14:35,912,141...36,012,564
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
B3glct |
beta 3-glucosyltransferase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of B3GLCT mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:5,255,521...5,346,807
Ensembl chr12:5,255,740...5,346,810
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BAX mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcam |
basal cell adhesion molecule (Lutheran blood group) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BCAM mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:88,542,971...88,557,358
Ensembl chr 1:79,415,017...79,429,403
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:35762964 PMID:37021957 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2L10 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 8:84,987,833...84,993,878
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BCL6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BDNF mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
|
|
G |
Bex1 |
brain expressed X-linked 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BEX2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:104,010,639...104,012,143
Ensembl chr X:99,219,014...99,220,958
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BHLHE40 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BHLHE41 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BHMT mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BID mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BNIP3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:64,106,809...64,135,749
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BRSK1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:78,162,944...78,193,598
Ensembl chr 1:69,134,565...69,160,365
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BTG2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of BZW1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:67,424,860...67,438,656
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C11h21orf91 |
similar to human chromosome 21 open reading frame 91 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of D16ERTD472E mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:30,716,034...30,749,292
Ensembl chr11:17,229,138...17,262,483
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of C5 protein |
CTD |
PMID:38954831 |
|
NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:74,715,483...74,746,669
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:88,317,124...88,349,718
Ensembl chr13:85,786,483...85,817,749
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:14,719,078...15,173,218
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CAMKK1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:58,135,872...58,159,023
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Cand2 |
cullin-associated and neddylation-dissociated 2 (putative) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CAND2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:148,835,050...148,864,039
Ensembl chr 4:148,835,053...148,863,153
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CASP3 mRNA |
CTD |
PMID:37839492 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CAT mRNA |
CTD |
PMID:28013214 PMID:39150890 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CBS mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CCDC3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:77,941,148...78,044,820
Ensembl chr17:73,035,045...73,135,337
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL5 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn4 |
cellular communication network factor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CCN4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:98,645,182...98,677,248
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CD36 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd93 |
CD93 molecule |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of CD93 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CD93 mRNA |
CTD |
PMID:38954831 PMID:39150890 |
|
NCBI chr 3:156,345,019...156,351,537
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdhr1 |
cadherin-related family member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDHR1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:12,863,696...12,883,579
Ensembl chr16:12,843,437...12,863,396
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK5R1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:33316053 PMID:35762964 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:37839492 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDKN1C mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDO1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:41,619,076...41,633,719
Ensembl chr18:39,432,474...39,447,296
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CEBPA mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:118,409,136...118,438,593
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cenpm |
centromere protein M |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CENPM mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:115,628,117...115,639,401
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cerk |
ceramide kinase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CERK mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:119,105,674...119,149,885
Ensembl chr 7:117,225,855...117,268,759
|
|
G |
Cfap299 |
cilia and flagella associated protein 299 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CFAP299 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:10,787,191...11,272,894
Ensembl chr14:10,787,203...11,272,943
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:140,496,712...140,510,057
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:71,390,328...71,395,023
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clip3 |
CAP-GLY domain containing linker protein 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CLIP3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:94,674,492...94,690,643
Ensembl chr 1:85,547,206...85,563,184
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:159,017,795...159,051,069
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmah |
cytidine monophospho-N-acetylneuraminic acid hydroxylase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CMAH mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:40,985,129...41,070,317
Ensembl chr17:40,583,667...40,642,275
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CMBL mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cntn2 |
contactin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CNTN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:46,497,269...46,528,112
Ensembl chr13:43,947,265...43,975,887
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:86,610,140...86,625,896
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Cntnap2 |
contactin associated protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CNTNAP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:75,109,358...77,366,258
Ensembl chr 4:74,109,472...76,362,027
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL10A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:39,737,536...39,744,518
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of COL18A1 protein |
CTD |
PMID:38954831 |
|
NCBI chr20:11,473,645...11,582,111
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL1A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL3A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL6A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL6A2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COL8A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:56,245,998...56,378,586
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of COMT mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpne8 |
copine 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CPNE8 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:123,494,864...123,669,060
Ensembl chr 7:121,615,294...121,790,377
|
|
G |
Cpz |
carboxypeptidase Z |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CPZ mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:79,448,242...79,471,557
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CREG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:80,552,779...80,565,272
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CRP protein |
CTD |
PMID:38954831 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CSF1 protein |
CTD |
PMID:38954831 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CSRNP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:128,582,364...128,594,163
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL12 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL13 protein |
CTD |
PMID:38954831 |
|
NCBI chr14:13,912,858...13,917,920
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CYB5A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:80,487,923...80,520,544
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 PMID:33983380 PMID:34597818 PMID:37552060 PMID:37788136 PMID:39150890 More...
|
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B1 mRNA diisobutyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 PMID:33983380 |
|
NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of CYP11B2 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP17A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 PMID:33983380 PMID:37788136 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 PMID:34597818 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions |
EXP ISO |
[diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in increased expression of CYP26B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CYP26B1 mRNA |
CTD |
PMID:37788136 PMID:39150890 |
|
NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CYP2F2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Dancr |
differentiation antagonizing non-protein coding RNA |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DANCR mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:34,126,956...34,127,936
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DCAF12L1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:128,572,969...128,576,588
Ensembl chr X:123,695,286...123,698,905
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:120,279,916...120,332,362
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:90,592,304...90,682,830
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DDIT4L mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DGKB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dglucy |
D-glutamate cyclase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DGLUCY mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:125,785,075...125,860,496
Ensembl chr 6:120,055,460...120,130,910
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of DHCR7 mRNA diisobutyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DHRS3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DKK2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:223,242,375...223,334,249
Ensembl chr 2:220,568,338...220,660,225
|
|
G |
Dnaaf10 |
dynein axonemal assembly factor 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of WDR92 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:91,618,649...91,639,828
Ensembl chr14:91,636,157...91,639,831
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DNER mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:116,431,158...116,782,218
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DPYSL3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:35,625,357...35,731,152
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DRD4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of DUSP4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:64,079,893...64,101,396
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:34,819,313...35,132,647
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:16,971,372...16,977,782
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:93,767,559...93,782,896
Ensembl chr11:80,263,162...80,278,428
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:139,036,576...139,042,074
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EGR1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elavl2 |
ELAV like RNA binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ELAVL2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Emb |
embigin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EMB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:49,069,087...49,125,050
|
|
G |
Emp2 |
epithelial membrane protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EMP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ENC1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:50,029,591...50,054,254
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Epha4 |
Eph receptor A4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EPHA4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Ermp1 |
endoplasmic reticulum metallopeptidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ERMP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:236,801,459...236,835,656
Ensembl chr 1:227,387,920...227,436,909
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ERRFI1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:167,909,271...167,943,168
Ensembl chr 5:162,626,560...162,660,256
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA diisobutyl phthalate results in increased activity of ESR1 protein |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esyt1 |
extended synaptotagmin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ESYT1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:1,513,381...1,530,836
Ensembl chr 7:928,848...946,199
|
|
G |
Etfdh |
electron transfer flavoprotein dehydrogenase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ETFDH mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:167,038,707...167,060,758
Ensembl chr 2:164,729,749...164,762,745
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ETV5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:92,113,171...92,170,758
Ensembl chr11:78,608,710...78,666,215
|
|
G |
Eva1a |
eva-1 homolog A, regulator of programmed cell death |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EVA1A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:116,151,595...116,200,827
Ensembl chr 4:114,593,341...114,643,011
|
|
G |
Eya2 |
EYA transcriptional coactivator and phosphatase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of EYA2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:174,754,772...174,938,035
Ensembl chr 3:154,335,400...154,518,793
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FAH mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:147,957,931...147,980,708
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,813,129...70,891,410
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FAM219A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:61,475,185...61,525,749
Ensembl chr 5:56,680,613...56,729,924
|
|
G |
Fam222a |
family with sequence similarity 222, member A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FAM222A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FAR1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:177,078,973...177,140,363
Ensembl chr 1:167,644,677...167,705,730
|
|
G |
Fbxl7 |
F-box and leucine-rich repeat protein 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FBXL7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:78,870,236...79,239,697
Ensembl chr 2:77,140,826...77,509,223
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FCGR3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:85,813,516...85,830,269
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of FDPS mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgf11 |
fibroblast growth factor 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FGF11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:55,015,232...55,020,773
Ensembl chr10:54,517,077...54,522,062
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of FGF2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FGF5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:11,627,906...11,650,243
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FGFR2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FHL2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Flcn |
folliculin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:45,088,164...45,107,581
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:181,583,801...181,596,464
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FOSB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
[Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein |
CTD |
PMID:34597818 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:86,277,678...86,286,954
Ensembl chr 1:86,277,678...86,286,954
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FZD2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:88,061,988...88,063,898
Ensembl chr10:87,561,326...87,565,334
|
|
G |
Fzd8 |
frizzled class receptor 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FZD8 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:62,007,849...62,015,485
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GADD45A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GALNT4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:35,811,904...35,814,445
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GANAB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:215,222,918...215,242,808
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GATA4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GDF15 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:26,571,952...26,600,225
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:138,707,970...138,715,279
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GLIPR2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:62,966,163...62,998,016
Ensembl chr 5:58,170,425...58,202,272
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GLS mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gmeb1 |
glucocorticoid modulatory element binding protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GMEB1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:149,703,035...149,746,474
Ensembl chr 5:144,420,555...144,462,602
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GPCPD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:140,240,574...140,285,469
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GPD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpr3 |
G protein-coupled receptor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GPR3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:150,695,406...150,698,526
Ensembl chr 5:145,411,510...145,414,590
|
|
G |
Gprin2 |
G protein regulated inducer of neurite outgrowth 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GPRIN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:9,496,452...9,512,672
Ensembl chr16:9,505,643...9,507,010
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPX1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gramd1b |
GRAM domain containing 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GRAMD1B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:49,551,642...49,790,965
Ensembl chr 8:40,659,182...40,893,925
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of GREM2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:89,310,897...89,403,856
Ensembl chr13:86,778,500...86,871,615
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
H3f3b |
H3.3 histone B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of H3F3B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,256,480...101,258,709 Ensembl chr13:101,256,480...101,258,709
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HADHA mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HADHB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Has2 |
hyaluronan synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HAS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HCK mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hmgb2 |
high mobility group box 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HMGB2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:37,721,374...37,723,950
Ensembl chr16:32,710,658...32,713,140 Ensembl chr 1:32,710,658...32,713,140
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HMGCS1 mRNA |
CTD |
PMID:28655647 PMID:33983380 PMID:39150890 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,745,430...81,747,181
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:80,041,598...80,057,700
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hp |
haptoglobin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:54,449,151...54,453,701
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD17B11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:5,997,893...6,047,816
Ensembl chr14:5,711,964...5,743,161
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 PMID:35762964 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of HSD3B3 mRNA diisobutyl phthalate results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:188,826,756...188,832,734
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HSDL2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HSPB8 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:45,835,899...45,866,449
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HSPD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of HTRA1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IDH3A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:74,161,761...74,200,651
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ier2 |
immediate early response 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IER2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:40,399,373...40,400,897
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IFNG protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IGFBP5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP6 protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:133,276,234...133,280,966
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IL13 protein |
CTD |
PMID:38954831 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of IL1B mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 9:84,443,109...84,446,010
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inpp5j |
inositol polyphosphate-5-phosphatase J |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of INPP5J mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:82,597,789...82,608,930
Ensembl chr14:78,374,161...78,385,326
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of INSL3 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of INSL3 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 PMID:33983380 PMID:37788136 |
|
NCBI chr16:18,432,668...18,434,539
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IRF2BP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:71,456,689...71,462,368
Ensembl chr19:54,560,128...54,566,642
|
|
G |
Irgm |
immunity-related GTPase M |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IRGM1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Irgq |
immunity-related GTPase Q |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of IRGQ mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:89,251,846...89,259,799
Ensembl chr 1:80,123,925...80,131,881
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ISG15 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itga11 |
integrin subunit alpha 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITGA11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:72,041,432...72,150,137
Ensembl chr 8:63,146,001...63,254,407
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITGA2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga7 |
integrin subunit alpha 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITGA7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:1,944,447...1,973,347
Ensembl chr 7:1,359,940...1,388,450
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITGB3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITIH5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:73,161,886...73,261,930
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Itprip |
inositol 1,4,5-trisphosphate receptor interacting protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ITPRIP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:256,704,087...256,727,661
Ensembl chr 1:246,762,472...246,786,408
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of JAG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of JUNB mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:40,081,126...40,082,910
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KANK4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:118,516,994...118,581,024
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KBTBD11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:81,318,596...81,340,334
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kctd10 |
potassium channel tetramerization domain containing 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KCTD10 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:47,890,777...47,909,391
Ensembl chr12:42,230,269...42,248,783
|
|
G |
Kctd11 |
potassium channel tetramerization domain containing 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KCTD11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:55,101,292...55,103,455
Ensembl chr10:54,599,754...54,604,760
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KDELR3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:111,079,218...111,101,600
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KIF5A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5A mRNA |
CTD |
PMID:37690569 |
|
NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KIF5C mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klf11 |
KLF transcription factor 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KLF11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:47,014,312...47,026,152
Ensembl chr 6:41,285,842...41,297,550
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KMT5A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:37,800,339...37,823,706
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KRT18 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of L1CAM protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr X:156,748,597...156,775,116
Ensembl chr X:151,597,277...151,623,857
|
|
G |
Laptm5 |
lysosomal protein transmembrane 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LAPTM5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:148,371,880...148,393,927
Ensembl chr 5:143,087,759...143,109,807
|
|
G |
Lats2 |
large tumor suppressor kinase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LATS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:35,940,632...35,992,225
Ensembl chr15:31,825,092...31,877,220
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LCN2 protein |
CTD |
PMID:31199487 PMID:38954831 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LEP protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LGR4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:96,447,858...96,548,899
|
|
G |
Lgr6 |
leucine-rich repeat-containing G protein-coupled receptor 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LGR6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:48,976,193...49,095,870
Ensembl chr13:46,424,383...46,543,945
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased secretion of LHB protein |
CTD |
PMID:37839492 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LIPE mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LPCAT1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:29,766,071...29,816,401
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LPIN1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LPL mRNA |
CTD |
PMID:30768133 PMID:39150890 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LRATD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:42,646,515...42,650,988
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LRG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:1,034,691...1,036,937
Ensembl chr 9:947,516...949,813
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:94,922,034...94,956,309
Ensembl chr 1:94,935,603...94,956,263
|
|
G |
Lrtm2 |
leucine-rich repeats and transmembrane domains 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of LRTM2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:154,158,165...154,180,389
Ensembl chr 4:152,485,866...152,500,377
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:108,521,783...108,527,012
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Mafk |
MAF bZIP transcription factor K |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MAFK mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:19,948,473...19,970,351
Ensembl chr12:14,833,984...14,837,048 Ensembl chr12:14,833,984...14,837,048
|
|
G |
Magee1 |
MAGE family member E1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MAGEE1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:74,254,848...74,258,395
Ensembl chr X:70,189,187...70,192,810
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MAP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:162,980,339...163,046,548
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mapre3 |
microtubule-associated protein, RP/EB family, member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MAPRE3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:31,233,736...31,278,626
Ensembl chr 6:25,513,800...25,558,881
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mboat1 |
membrane bound O-acyltransferase domain containing 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MBOAT1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,331,422...34,445,088
|
|
G |
Mboat7 |
membrane bound O-acyltransferase domain containing 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MBOAT7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:74,440,618...74,454,896
Ensembl chr 1:65,525,213...65,539,538
|
|
G |
Mccc1 |
methylcrotonyl-CoA carboxylase subunit 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MCCC1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:120,727,313...120,779,334
Ensembl chr 2:118,799,150...118,851,222
|
|
G |
Me3 |
malic enzyme 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ME3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:143,534,139...143,733,132
|
|
G |
Mex3b |
mex-3 RNA binding family member B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MEX3B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:146,264,319...146,268,554
Ensembl chr 1:136,855,130...136,859,354
|
|
G |
Mfsd4a |
major facilitator superfamily domain containing 4A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MFSD4A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:46,015,321...46,062,633
Ensembl chr13:43,469,488...43,510,467
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MGLL mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MGST1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:159,209,525...159,209,618
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr 8:99,222,982...99,223,058
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:185,484,791...185,493,961
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:27,178,158...27,213,675
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MME mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpp2 |
MAGUK p55 scaffold protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MPP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:87,511,638...87,544,710
Ensembl chr10:87,011,434...87,043,896
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MPZL2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:54,244,920...54,256,064
Ensembl chr 8:45,348,285...45,359,298
|
|
G |
Mrgbp |
MRG domain binding protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MRGBP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:167,697,129...167,700,592
Ensembl chr 3:167,697,185...167,700,592
|
|
G |
Mrpl1 |
mitochondrial ribosomal protein L1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MRPL1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:13,604,498...13,663,633
Ensembl chr14:13,300,522...13,359,721
|
|
G |
Mtss2 |
MTSS I-BAR domain containing 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MTSS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:55,602,180...55,623,955
Ensembl chr19:38,693,194...38,713,507
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MTUS1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:57,905,991...58,051,466
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of MVD mRNA |
CTD |
PMID:33983380 |
|
NCBI chr19:67,404,911...67,414,974
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Myo10 |
myosin X |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MYO10 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:76,100,987...76,303,030
|
|
G |
Nab2 |
Ngfi-A binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NAB2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:65,382,863...65,389,527
Ensembl chr 7:63,497,589...63,503,989
|
|
G |
Nacad |
NAC alpha domain containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NACAD mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:81,465,299...81,473,866
Ensembl chr14:81,465,299...81,473,781
|
|
G |
Ncald |
neurocalcin delta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NCALD mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:70,417,683...70,849,763
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NCEH1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NCS1 mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Ndn |
necdin, MAGE family member |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NDN mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:125,261,059...125,262,658
Ensembl chr 1:115,849,105...115,850,767
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,357,470...9,393,465
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NDUFS1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:72,040,286...72,073,605
Ensembl chr 9:64,546,225...64,579,893
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:84,044,428...84,054,413
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:108,845,462...109,709,858
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of NFE2L2 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NFE2L2 mRNA |
CTD |
PMID:37021957 PMID:39150890 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfe2l3 |
NFE2 like bZIP transcription factor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NFE2L3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:81,837,404...81,865,258
Ensembl chr 4:80,506,756...80,534,629
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,012,077...81,030,305
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC9A3R1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:100,902,165...100,919,265
Ensembl chr10:100,403,069...100,420,598
|
|
G |
Nmrk1 |
nicotinamide riboside kinase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NMRK1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:225,475,975...225,503,414
Ensembl chr 1:216,049,437...216,076,791
|
|
G |
Nnat |
neuronatin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NNAT mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:166,646,373...166,648,845
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nol4 |
nucleolar protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NOL4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:14,207,303...14,569,697
Ensembl chr18:13,932,510...14,296,286
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NOS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch4 |
notch receptor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NOTCH4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:4,164,969...4,189,072
Ensembl chr20:4,160,445...4,184,465
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NPL mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:68,205,602...68,247,940
Ensembl chr13:65,655,118...65,697,372
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:54,707,658...54,711,786
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NR1H4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity affects binding |
ISO |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NR4A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NR4A2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NR4A3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrbp2 |
nuclear receptor binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NRBP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:109,679,330...109,685,656
Ensembl chr 7:107,799,497...107,805,230
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:213,155,673...213,271,526
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:155,817,301...155,848,224
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NSG1 mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr14:76,861,079...76,882,822
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Ntn4 |
netrin 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NTN4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:30,073,637...30,187,407
Ensembl chr 7:28,186,611...28,300,390
|
|
G |
Nup210 |
nucleoporin 210 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NUP210 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:125,068,736...125,167,238
Ensembl chr 4:123,511,559...123,609,874
|
|
G |
Nxf3 |
nuclear RNA export factor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of NXF3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:103,817,508...103,842,038
Ensembl chr X:99,025,901...99,039,261
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:31,918,512...31,956,261
Ensembl chr 3:11,520,729...11,558,239
|
|
G |
Olfml3 |
olfactomedin-like 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of OLFML3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:191,244,221...191,247,050
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of OPRL1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:189,209,495...189,225,406
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Osgin2 |
oxidative stress induced growth inhibitor family member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of OSGIN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:29,500,406...29,519,340
Ensembl chr 5:29,500,408...29,520,831
|
|
G |
P4ha2 |
prolyl 4-hydroxylase subunit alpha 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of P4HA2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:38,743,894...38,772,741
Ensembl chr10:38,243,139...38,287,314
|
|
G |
Palmd |
palmdelphin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PALMD mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:204,889,533...204,941,519
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PAPSS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Pcca |
propionyl-CoA carboxylase subunit alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCCA mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:106,034,586...106,374,908
Ensembl chr15:99,627,982...99,968,266
|
|
G |
Pcdhga11 |
protocadherin gamma subfamily A, 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCDHGA11 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:29,834,606...29,919,095
Ensembl chr18:29,493,954...29,667,868
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:49,229,185...49,331,186
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCSK1N mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:17,251,963...17,255,405
Ensembl chr X:14,580,038...14,583,566
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCSK2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:151,333,938...151,636,628
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pcsk5 |
proprotein convertase subtilisin/kexin type 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCSK5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:224,263,823...224,694,350
Ensembl chr 1:214,837,927...215,267,600
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PCSK9 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:126,440,102...126,462,507
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1A, choline |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PCYT1A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:81,818,914...81,862,623
Ensembl chr11:68,313,882...68,357,357
|
|
G |
Pde1b |
phosphodiesterase 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDE1B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:136,505,834...136,533,034
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pde3a |
phosphodiesterase 3A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDE3A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:174,172,868...174,438,274
|
|
G |
Pde3b |
phosphodiesterase 3B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDE3B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:178,041,207...178,204,503
Ensembl chr 1:168,607,022...168,769,334
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDE4B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde4d |
phosphodiesterase 4D |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDE4D mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased secretion of PDGFB protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfc |
platelet derived growth factor C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDGFC mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:168,613,409...168,791,575
Ensembl chr 2:166,316,803...166,493,433
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of PDK4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdzrn3 |
PDZ domain containing RING finger 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PDZRN3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:135,327,082...135,553,294
Ensembl chr 4:133,770,736...133,996,959
|
|
G |
Per1 |
period circadian regulator 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PER1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:54,299,002...54,313,804
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pex5l |
peroxisomal biogenesis factor 5-like |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PEX5L mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:117,623,199...117,836,772
Ensembl chr 2:115,700,972...115,913,628
|
|
G |
Pfn2 |
profilin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PFN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:142,067,104...142,072,938
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PHOSPHO1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:81,258,810...81,266,345
Ensembl chr10:80,760,792...80,770,342
|
|
G |
Phtf1 |
putative homeodomain transcription factor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PHTF1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:194,161,343...194,249,925
Ensembl chr 2:191,473,130...191,512,078
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLAU mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plcl2 |
phospholipase C-like 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLCL2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:3,529,117...3,713,712
Ensembl chr 9:3,292,695...3,477,009
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of PLIN1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of PLIN1 mRNA |
CTD |
PMID:37021957 PMID:39150890 |
|
NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLIN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:106,202,634...106,258,748
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Plin5 |
perilipin 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLIN5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:1,026,910...1,033,352
Ensembl chr 9:939,747...946,120
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLPP3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Plpp7 |
phospholipid phosphatase 7 (inactive) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLPP7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:35,782,215...35,796,577
Ensembl chr 3:15,384,492...15,398,883
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:105,196,312...105,306,252
Ensembl chr 8:96,317,849...96,385,195
|
|
G |
Pltp |
phospholipid transfer protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of PLTP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:153,574,825...153,592,647
|
|
G |
Plxnc1 |
plexin C1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PLXNC1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases activity increases expression |
ISO |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:37021957 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PRDM1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:49,542,465...49,564,088
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:128,094,686...128,155,592
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PRKAR2B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Procr |
protein C receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PROCR mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:164,714,727...164,718,994
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:132,096,888...132,101,070
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Prss23 |
serine protease 23 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PRSS23 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Prxl2a |
peroxiredoxin like 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PRXL2A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:16,900,697...16,920,521
Ensembl chr16:16,866,603...16,886,433
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PTGER2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:34,575,643...34,586,987
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PTGS2 mRNA |
CTD |
PMID:33316053 PMID:39150890 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PTPN5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of PTPRN mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr 9:84,189,676...84,205,364
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PTX3 protein |
CTD |
PMID:37552060 PMID:38954831 |
|
NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,500,060...70,537,711
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 5:128,859,034...128,926,087
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 8:112,574,223...112,642,911
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Ralgds |
ral guanine nucleotide dissociation stimulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RALGDS mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:32,237,644...32,278,045
Ensembl chr 3:11,839,416...11,880,059
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RAMP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:99,213,031...99,263,696
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rarg |
retinoic acid receptor, gamma |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RARG mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RARRES2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rasgef1b |
RasGEF domain family, member 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RASGEF1B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:10,164,366...10,684,184
Ensembl chr14:9,860,247...10,379,741
|
|
G |
Rasl11b |
RAS-like family 11 member B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RASL11B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:34,369,029...34,373,250
Ensembl chr14:34,014,509...34,019,152
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RBP4 protein |
CTD |
PMID:38954831 |
|
NCBI chr 1:245,306,349...245,313,551
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rbpms |
RNA binding protein, mRNA processing factor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RBPMS mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:64,942,159...65,098,504
Ensembl chr16:58,239,474...58,395,426
|
|
G |
Rcan2 |
regulator of calcineurin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RCAN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:24,456,861...24,674,234
Ensembl chr 9:16,959,480...17,174,856
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:84,213,844...84,220,186
Ensembl chr 9:76,764,590...76,778,722
|
|
G |
Retsat |
retinol saturase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RETSAT mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RGS2 mRNA |
CTD |
PMID:37552060 PMID:39150890 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RGS4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:84,469,593...84,475,884
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rnf125 |
ring finger protein 125 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RNF125 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:12,528,995...12,550,646
Ensembl chr18:12,253,852...12,275,983
|
|
G |
Rnf145 |
ring finger protein 145 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RNF145 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:29,006,391...29,050,788
Ensembl chr10:29,011,548...29,050,781
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:75,877,111...75,886,253
Ensembl chr 5:75,876,003...75,886,191
|
|
G |
Rras2 |
RAS related 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of RRAS2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:177,668,143...177,737,551
Ensembl chr 1:168,233,693...168,303,111
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:96,348,613...96,373,554
Ensembl chr11:82,844,309...82,869,466
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr13:82,276,330...82,318,097
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Samd4b |
sterile alpha motif domain containing 4B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SAMD4B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:92,816,955...92,855,243
Ensembl chr 1:83,689,413...83,713,853
|
|
G |
Scara5 |
scavenger receptor class A, member 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SCARA5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:44,055,576...44,160,593
Ensembl chr15:39,880,035...39,983,373
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:33983380 |
|
NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd4 |
stearoyl-coenzyme A desaturase 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SCD4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:253,152,519...253,165,216
Ensembl chr 1:243,203,881...243,215,148
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:85,280,253...85,322,484
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scg5 |
secretogranin V |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SCG5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:120,998,420...121,042,881
Ensembl chr 3:100,544,099...100,588,463
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:49,527,529...49,550,019
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:84,962,450...85,024,577
Ensembl chr 4:83,632,131...83,693,852
|
|
G |
Selenop |
selenoprotein P |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SELENOP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Sema7a |
semaphorin 7A (John Milton Hagen blood group) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SEMA7A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:67,244,318...67,267,060
Ensembl chr 8:58,348,448...58,370,536
|
|
G |
Serpinb1a |
serpin family B member 1A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SERPINB1A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:24,051,933...24,065,032
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinf1 |
serpin family F member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of SERPINF1 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SERPINF1 mRNA |
CTD |
PMID:38954831 PMID:39150890 |
|
NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SFRP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:75,278,325...75,316,736
Ensembl chr16:68,575,763...68,614,286
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SFRP2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sh3bp4 |
SH3-domain binding protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SH3BP4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 9:97,107,877...97,186,878
Ensembl chr 9:89,660,156...89,739,163
|
|
G |
Sh3bp5 |
SH3-domain binding protein 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SH3BP5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,583,465...6,698,975
|
|
G |
Sh3bp5l |
SH3 binding domain protein 5 like |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SH3BP5L mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:43,012,902...43,027,319
Ensembl chr10:42,512,552...42,530,221
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:145,533,728...145,664,881
Ensembl chr 1:136,124,499...136,255,584
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:57,686,701...57,747,735
Ensembl chr18:55,416,413...55,483,083
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:10,717,320...10,739,539
Ensembl chr 7:10,066,705...10,088,926
|
|
G |
Sik1 |
salt-inducible kinase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SIK1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Six4 |
SIX homeobox 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SIX4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:97,538,202...97,551,872
Ensembl chr 6:91,802,329...91,815,992
|
|
G |
Slain1 |
SLAIN motif family, member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLAIN1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:86,897,476...86,957,113
Ensembl chr15:80,482,367...80,542,350
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC12A2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:53,546,263...53,614,478
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc12a7 |
solute carrier family 12 member 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC12A7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:31,301,243...31,382,825
Ensembl chr 1:29,472,692...29,554,302
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,789,874...63,817,441
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc13a5 |
solute carrier family 13 member 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC13A5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:57,364,806...57,389,500
Ensembl chr10:56,866,249...56,890,945
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC16A3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC16A6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a6 |
solute carrier family 1 member 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC1A6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:11,492,422...11,521,007
Ensembl chr 7:10,841,837...10,870,449
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC20A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:136,880,360...136,894,255
Ensembl chr 3:116,427,098...116,441,051
|
|
G |
Slc24a3 |
solute carrier family 24 member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC24A3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:153,005,418...153,504,497
Ensembl chr 3:132,551,595...133,051,192
|
|
G |
Slc25a15 |
solute carrier family 25 member 15 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC25A15 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:76,334,037...76,357,325
Ensembl chr16:69,634,414...69,653,010
|
|
G |
Slc25a51 |
solute carrier family 25, member 51 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC25A51 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:64,445,610...64,459,172
Ensembl chr 5:59,649,744...59,663,581
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC27A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:18,311,859...18,337,024
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc27a6 |
solute carrier family 27 member 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC27A6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:54,238,697...54,297,595
Ensembl chr18:52,041,074...52,099,414
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:16,967,047...16,998,276
Ensembl chr12:11,853,540...11,874,834
|
|
G |
Slc36a2 |
solute carrier family 36 member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC36A2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:39,778,667...39,806,781
Ensembl chr10:39,278,046...39,306,082
|
|
G |
Slc38a3 |
solute carrier family 38, member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC38A3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:117,202,534...117,220,310
Ensembl chr 8:108,323,894...108,339,988
|
|
G |
Slc38a5 |
solute carrier family 38, member 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC38A5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:16,885,701...16,894,470
Ensembl chr X:14,213,729...14,222,498
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC5A7 mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr 9:7,922,693...7,953,509
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slc6a7 |
solute carrier family 6 member 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC6A7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:56,718,849...56,737,702
Ensembl chr18:54,448,464...54,467,319
|
|
G |
Slc7a7 |
solute carrier family 7 member 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC7A7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:31,792,122...31,852,732
Ensembl chr15:27,822,091...27,865,648
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC7A8 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:32,153,016...32,212,715
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLC8A1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:112,467,739...112,551,923
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Slfn2 |
schlafen family member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLFN2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:68,450,861...68,457,198
Ensembl chr10:67,953,171...67,959,458
|
|
G |
Slit3 |
slit guidance ligand 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SLIT3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:20,075,929...20,660,704
Ensembl chr10:19,571,684...20,156,634
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SMAD7 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:8,964,107...8,967,234
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SMPD3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:51,072,209...51,155,639
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:167,451,272...167,456,945
|
|
G |
Snn |
stannin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SNN mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:5,079,885...5,088,565
Ensembl chr10:4,572,376...4,584,021 Ensembl chr 1:4,572,376...4,584,021
|
|
G |
Sntb1 |
syntrophin, beta 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SNTB1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:88,950,642...89,219,017
Ensembl chr 7:87,060,926...87,329,315
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SOAT1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:71,105,178...71,147,776
Ensembl chr13:68,552,317...68,597,494
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SOCS3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SORD mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in increased expression of SOX9 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SOX9 mRNA |
CTD |
PMID:22112501 PMID:39150890 |
|
NCBI chr10:98,305,744...98,311,250
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spata13 |
spermatogenesis associated 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SPATA13 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:34,778,479...34,907,645
Ensembl chr15:34,778,473...34,905,114
|
|
G |
Specc1 |
sperm antigen with calponin homology and coiled-coil domains 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SPECC1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:47,138,351...47,412,311
Ensembl chr10:46,638,809...46,912,802
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SQLE mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srpx2 |
sushi-repeat-containing protein, X-linked 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SRPX2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:101,399,748...101,425,486
Ensembl chr X:97,106,561...97,132,195
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA] |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 PMID:33983380 PMID:34597818 PMID:35762964 PMID:37552060 PMID:37788136 PMID:37839492 More...
|
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:203,330,325...203,411,325
Ensembl chr 1:193,900,718...193,981,723
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:44,716,825...44,734,776
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Ston2 |
stonin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of STON2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:110,567,485...110,676,376
Ensembl chr 6:110,567,485...110,676,376
|
|
G |
Suclg2 |
succinate-CoA ligase GDP-forming subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SUCLG2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:129,623,833...129,893,937
Ensembl chr 4:128,067,033...128,337,170
|
|
G |
Sulf1 |
sulfatase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SULF1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:6,362,911...6,525,584
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of SYT11 mRNA |
CTD |
PMID:31199487 PMID:39150890 |
|
NCBI chr 2:176,503,845...176,530,354
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:78,320,034...78,327,750
Ensembl chr 1:69,277,351...69,285,067
|
|
G |
Tbl1xr1 |
TBL1X/Y related 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TBL1XR1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:106,718,811...106,857,989
Ensembl chr 2:104,801,721...104,929,055
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:71,177,082...71,186,275
Ensembl chr10:70,679,518...70,688,529
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:31,117,839...31,126,575
Ensembl chr 6:25,397,937...25,405,880
|
|
G |
Tchhl1 |
trichohyalin-like 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TCHHL1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:181,818,424...181,821,666
Ensembl chr 2:179,135,796...179,138,202
|
|
G |
Tcp11x2 |
t-complex 11 family, X-linked 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TCP11X2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:102,884,405...103,432,445
Ensembl chr X:98,591,189...98,640,763
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:22,961,005...22,979,711
Ensembl chr 9:15,463,739...15,472,954
|
|
G |
Tdrp |
testis development related protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TDRP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:75,624,047...75,652,635
Ensembl chr16:75,624,907...75,652,420
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TFRC mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TGFA mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TGM2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Thbs3 |
thrombospondin 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of THBS3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:176,919,549...176,931,357
Ensembl chr 2:174,621,812...174,633,594
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of THBS4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:25,718,219...25,760,345
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:10,115,954...10,465,231
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Thsd4 |
thrombospondin type 1 domain containing 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of THSD4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 8:69,280,397...69,880,144
Ensembl chr 8:60,386,875...61,024,995
|
|
G |
Thsd7b |
thrombospondin type 1 domain containing 7B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of THSD7B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr13:43,320,895...44,219,546
Ensembl chr13:40,768,570...41,666,501
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlnrd1 |
talin rod domain containing 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TLNRD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:147,273,475...147,275,494
Ensembl chr 1:137,864,343...137,866,359
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:212,785,217...212,789,572
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:57,937,873...58,225,372
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:9,837,055...9,862,843
Ensembl chr12:9,837,055...9,862,840
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:101,796,623...101,807,471
Ensembl chr X:97,503,350...97,514,197
|
|
G |
Tmem50b |
transmembrane protein 50B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TMEM50B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:44,290,805...44,323,650
Ensembl chr11:30,804,837...30,837,661
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:112,398,308...112,469,732
Ensembl chr 6:106,672,934...106,736,990
|
|
G |
Tmsb15b2 |
thymosin beta 15B2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TMSB15B2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:105,090,980...105,093,094
Ensembl chr X:100,298,514...100,300,886
|
|
G |
Tmx1 |
thioredoxin-related transmembrane protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TMX1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:94,696,699...94,707,751
Ensembl chr 6:88,960,695...88,971,301
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TNFAIP6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of TNFRSF11B protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tob2 |
transducer of ERBB2, 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TOB2 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:113,361,148...113,372,688
|
|
G |
Tor4a |
torsin family 4, member A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TOR4A mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 3:28,402,454...28,406,141
Ensembl chr 3:8,002,023...8,008,042
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TPI1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TRAP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:11,971,259...12,005,306
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trarg1 |
trafficking regulator of GLUT4 (SLC2A4) 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TRARG1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr10:62,019,281...62,039,666
Ensembl chr10:61,521,107...61,541,494
|
|
G |
Trib1 |
tribbles pseudokinase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TRIB1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:91,206,579...91,214,731
|
|
G |
Trim6 |
tripartite motif containing 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TRIM6 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 1:168,095,619...168,108,809
Ensembl chr 1:158,683,746...158,696,914
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[diisobutyl phthalate results in increased abundance of mono-isobutyl phthalate] which results in decreased secretion of TSHB protein |
CTD |
PMID:29734584 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:79,125,564...79,144,137
Ensembl chr 1:70,053,324...70,071,845
|
|
G |
Ttyh3 |
tweety family member 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TTYH3 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr12:19,110,973...19,139,379
Ensembl chr12:13,997,045...14,025,459
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB2B protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr17:30,953,086...30,956,133
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB3 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB3 mRNA |
CTD |
PMID:31199487 PMID:37690569 PMID:39150890 |
|
NCBI chr19:68,365,687...68,374,741
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB4A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB4A mRNA |
CTD |
PMID:31199487 PMID:37690569 PMID:39150890 |
|
NCBI chr 9:2,004,836...2,012,281
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TXNIP mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TXNRD1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:50,282,510...50,430,034
Ensembl chr 8:41,388,341...41,532,201
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 5:151,613,411...151,637,274
Ensembl chr 5:146,329,842...146,353,526
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of UCP1 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Unc5d |
unc-5 netrin receptor D |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of UNC5D mRNA |
CTD |
PMID:39150890 |
|
NCBI chr16:69,563,099...70,109,862
Ensembl chr16:62,860,174...63,401,143
|
|
G |
Usp18 |
ubiquitin specific peptidase 18 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of USP18 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:156,143,770...156,171,292
Ensembl chr 4:154,471,592...154,499,144
|
|
G |
Vamp5 |
vesicle-associated membrane protein 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of VAMP5 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:105,982,004...105,993,247
Ensembl chr 4:104,423,820...104,426,212
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of VEGFD mRNA |
CTD |
PMID:39150890 |
|
NCBI chr X:33,704,582...33,740,305
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vgll4 |
vestigial-like family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of VGLL4 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:147,925,630...148,038,519
Ensembl chr 4:147,927,034...148,038,471
|
|
G |
Vopp1 |
VOPP1 WW domain binding protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of VOPP1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:87,363,678...87,432,747
Ensembl chr 4:87,363,477...87,450,375
|
|
G |
Wfs1 |
wolframin ER transmembrane glycoprotein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of WFS1 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr14:78,035,205...78,059,718
Ensembl chr14:73,810,404...73,835,602
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:83,778,552...83,792,186
Ensembl chr 9:76,329,882...76,343,523
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,135,362...89,157,065
Ensembl chr10:88,635,331...88,657,035
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:112,019,721...112,068,454
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of XDH mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Zbtb8b |
zinc finger and BTB domain containing 8b |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZBTB8B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 5:141,765,925...141,781,619
Ensembl chr 5:141,766,309...141,781,600
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:120,299,138...120,302,465
Ensembl chr X:115,433,259...115,436,692
|
|
G |
Zdhhc23 |
zinc finger DHHC-type palmitoyltransferase 23 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZDHHC23 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr11:56,718,702...56,735,063
Ensembl chr11:56,718,826...56,734,194
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:101,775,916...101,951,135
Ensembl chr 7:99,886,954...100,054,274
|
|
G |
Zfp280b |
zinc finger protein 280B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZFP280B mRNA |
CTD |
PMID:39150890 |
|
NCBI chr20:12,626,550...12,641,383
Ensembl chr20:12,627,106...12,646,683
|
|
G |
Zfp330 |
zinc finger protein 330 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZFP330 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:25,313,655...25,324,958
Ensembl chr19:25,313,655...25,324,958
|
|
G |
Zfp467 |
zinc finger protein 467 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZFP467 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr 4:78,716,473...78,725,829
Ensembl chr 4:77,385,758...77,392,229
|
|
G |
Zfp503 |
zinc finger protein 503 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZFP503 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr15:2,362,450...2,366,238
Ensembl chr15:2,313,060...2,316,848
|
|
G |
Zfp791 |
zinc finger protein 791 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of ZFP791 mRNA |
CTD |
PMID:39150890 |
|
NCBI chr19:23,018,418...23,033,580
Ensembl chr19:23,018,918...23,033,504
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:183,944,840...183,956,619
Ensembl chr 1:174,513,511...174,525,288
|
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr18:30,937,670...31,023,786
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:200,024,056...200,025,466
|
|
G |
Ggt5 |
gamma-glutamyltransferase 5 |
increases expression |
EXP |
isobutyl nitrite results in increased expression of GGT5 mRNA |
CTD |
PMID:9374738 |
|
NCBI chr20:13,042,694...13,070,960
Ensembl chr20:13,043,257...13,071,450
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HMOX1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HSPA4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of PF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of SMAD7 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFA mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFD mRNA |
CTD |
PMID:16288974 |
|
NCBI chr X:33,704,582...33,740,305
Ensembl chr X:30,074,163...30,108,295
|
|